

# Attention Hospital Physician

## WARNING

### Potential for Incorrect Blood Glucose Reading

22 March 2023

Dear Hospital Physician,

Baxter Healthcare Pty Ltd. would like to notify you of **important safety information** involving patients who use **EXTRANEAL** (icodextrin) peritoneal dialysis solution and who may require the use of blood glucose monitors and test strips.

**Patients receiving EXTRANEAL (icodextrin) peritoneal dialysis solution may have incorrect blood glucose results when using particular blood glucose monitors and test strips.**

**ONLY use glucose monitors and test strips that are glucose-specific. These methods are common in clinical laboratories. Contact the manufacturer of the glucose monitors and test strips to determine the method that is used. Visit [www.glucosafety.com](http://www.glucosafety.com) for additional information, including a glucose monitor compatibility list.**

The term “glucose-specific” applies to monitors or test strips that are not affected by the presence of maltose or certain other sugars. Because **EXTRANEAL** (icodextrin) peritoneal dialysis solution results in elevated blood levels of maltose, only glucose-specific monitors and test strips should be used.

**DO NOT use glucose monitors or test strips that utilize glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods. In addition, some but not all monitors or test strips that utilize a glucose dehydrogenase flavin-adenine dinucleotide (GDH-FAD) method should not be used.** Use of these methods may result in falsely elevated blood glucose readings in patients using **EXTRANEAL** (icodextrin) due to maltose interference. A blood glucose reading with these monitors that appears to be within the normal range in a patient on **EXTRANEAL** (icodextrin) may mask true hypoglycemia (low blood sugar). This would cause a patient or health care professional not to take the appropriate steps to bring the blood sugar into a normal range. A falsely elevated blood glucose reading could cause a patient to get more insulin than needed. Both of these situations can lead to life-threatening events, including loss of consciousness, coma, neurological damage or death.

Additional considerations for patients who use **EXTRANEAL** (icodextrin):

1. Discontinuing **EXTRANEAL** (icodextrin) use will not immediately address the risk for the potential interference with glucose monitors. Falsely elevated glucose levels may result up to two weeks following cessation of **EXTRANEAL** (icodextrin).
2. To determine what type of method is used for monitoring glucose levels, review the labeling for BOTH the glucose monitor and the test strips used. If in doubt, contact the manufacturer of the glucose monitors and test strips to determine the method that is used.

**Baxter**

3. If your hospital uses electronic medical records, the above information describing the potential for interference with blood glucose monitors or test strips needs to be entered in a suitable field readily apparent to all users.

For further information, refer to **EXTRANEAL** (icodextrin) prescribing information or visit [www.glucosesafety.com](http://www.glucosesafety.com)

I hope this information is helpful to you. If you have additional questions about **EXTRANEAL** (icodextrin), please contact your Baxter Renal Representative.



Kuljinder Singh  
Senior Director Medical Affairs, Japan & ANZ  
Baxter Healthcare Pty Limited

Baxter Healthcare Pty Ltd, 1 Baxter Drive, Old Toongabbie, NSW 2146, Australia. Tel: 1800 229 837.  
[www.baxterhealthcare.com.au](http://www.baxterhealthcare.com.au)

Baxter Healthcare Ltd, 33 Vestey Drive, Mt Wellington, Auckland, New Zealand. Tel: 0800 229 837.  
[www.baxter.co.nz](http://www.baxter.co.nz)

BAXTER and **EXTRANEAL** are trademarks of Baxter International Inc.  
Date of Preparation, 22 March 2023.

# Attention Hospital Nurse

## WARNING

### Potential for Incorrect Blood Glucose Reading

22 March 2023

Dear Hospital Nurse,

Baxter Healthcare Pty Ltd. would like to notify you of **important safety information** involving patients who use **EXTRANEAL** (icodextrin) peritoneal dialysis solution and who may require the use of blood glucose monitors and test strips.

**Patients receiving EXTRANEAL (icodextrin) peritoneal dialysis solution may have incorrect blood glucose results when using particular blood glucose monitors and test strips.**

**ONLY use glucose monitors and test strips that are glucose-specific. These methods are common in clinical laboratories. Contact the manufacturer of the glucose monitors and test strips to determine the method that is used. Visit [www.glucosafety.com](http://www.glucosafety.com) for additional information, including a glucose monitor compatibility list.**

The term “glucose-specific” applies to monitors or test strips that are not affected by the presence of maltose or certain other sugars. Because **EXTRANEAL** (icodextrin) peritoneal dialysis solution results in elevated blood levels of maltose, only glucose-specific monitors and test strips should be used.

**DO NOT use glucose monitors or test strips that utilize glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods. In addition, some but not all monitors or test strips that utilize a glucose dehydrogenase flavin-adenine dinucleotide (GDH-FAD) method should not be used.** Use of these methods may result in falsely elevated blood glucose readings in patients using **EXTRANEAL** (icodextrin) due to maltose interference. A blood glucose reading with these monitors that appears to be within the normal range in a patient on **EXTRANEAL** (icodextrin) may mask true hypoglycemia (low blood sugar). This would cause a patient or health care professional not to take the appropriate steps to bring the blood sugar into a normal range. A falsely elevated blood glucose reading could cause a patient to get more insulin than needed. Both of these situations can lead to life-threatening events, including loss of consciousness, coma, neurological damage or death.

Additional considerations for patients who use **EXTRANEAL** (icodextrin):

1. Discontinuing **EXTRANEAL** (icodextrin) use will not immediately address the risk for the potential interference with glucose monitors. Falsely elevated glucose levels may result up to two weeks following cessation of **EXTRANEAL** (icodextrin).
2. To determine what type of method is used for monitoring glucose levels, review the labeling for BOTH the glucose monitor and the test strips used. If in doubt, contact the manufacturer of the glucose monitors and test strips to determine the method that is used.

**Baxter**

3. If your hospital uses electronic medical records, the above information describing the potential for interference with blood glucose monitors or test strips needs to be entered in a suitable field readily apparent to all users.

For further information, refer to **EXTRANEAL** (icodextrin) prescribing information or visit [www.glucosesafety.com](http://www.glucosesafety.com)

I hope this information is helpful to you. If you have additional questions about **EXTRANEAL** (icodextrin), please contact your Baxter Renal Representative.



Kuljinder Singh  
Senior Director Medical Affairs, Japan & ANZ  
Baxter Healthcare Pty Limited

Baxter Healthcare Pty Ltd, 1 Baxter Drive, Old Toongabbie, NSW 2146, Australia. Tel: 1800 229 837.  
[www.baxterhealthcare.com.au](http://www.baxterhealthcare.com.au)

Baxter Healthcare Ltd, 33 Vestey Drive, Mt Wellington, Auckland, New Zealand. Tel: 0800 229 837.  
[www.baxter.co.nz](http://www.baxter.co.nz)

BAXTER and EXTRANEAL are trademarks of Baxter International Inc.  
Date of Preparation, 22 March 2023.

# Attention Hospital Admissions

## WARNING

### Potential for Incorrect Blood Glucose Reading

22 March 2023

Dear Hospital Admissions,

Baxter Healthcare Pty Ltd. would like to notify you of **important safety information** involving patients who use **EXTRANEAL** (icodextrin) peritoneal dialysis solution and who may require the use of blood glucose monitors and test strips.

**Patients receiving EXTRANEAL (icodextrin) peritoneal dialysis solution may have incorrect blood glucose results when using particular blood glucose monitors and test strips.**

**ONLY use glucose monitors and test strips that are glucose-specific. These methods are common in clinical laboratories. Contact the manufacturer of the glucose monitors and test strips to determine the method that is used. Visit [www.glucosafety.com](http://www.glucosafety.com) for additional information, including a glucose monitor compatibility list.**

The term “glucose-specific” applies to monitors or test strips that are not affected by the presence of maltose or certain other sugars. Because **EXTRANEAL** (icodextrin) peritoneal dialysis solution results in elevated blood levels of maltose, only glucose-specific monitors and test strips should be used.

**DO NOT use glucose monitors or test strips that utilize glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods. In addition, some but not all monitors or test strips that utilize a glucose dehydrogenase flavin-adenine dinucleotide (GDH-FAD) method should not be used.** Use of these methods may result in falsely elevated blood glucose readings in patients using **EXTRANEAL** (icodextrin) due to maltose interference. A blood glucose reading with these monitors that appears to be within the normal range in a patient on **EXTRANEAL** (icodextrin) may mask true hypoglycemia (low blood sugar). This would cause a patient or health care professional not to take the appropriate steps to bring the blood sugar into a normal range. A falsely elevated blood glucose reading could cause a patient to get more insulin than needed. Both of these situations can lead to life-threatening events, including loss of consciousness, coma, neurological damage or death.

Additional considerations for patients who use **EXTRANEAL** (icodextrin):

1. Discontinuing **EXTRANEAL** (icodextrin) use will not immediately address the risk for the potential interference with glucose monitors. Falsely elevated glucose levels may result up to two weeks following cessation of **EXTRANEAL** (icodextrin).
2. To determine what type of method is used for monitoring glucose levels, review the labeling for BOTH the glucose monitor and the test strips used. If in doubt, contact the manufacturer of the glucose monitors and test strips to determine the method that is used.

**Baxter**

3. If your hospital uses electronic medical records, the above information describing the potential for interference with blood glucose monitors or test strips needs to be entered in a suitable field readily apparent to all users.

For further information, refer to **EXTRANEAL** (icodextrin) prescribing information or visit [www.glucosesafety.com](http://www.glucosesafety.com)

I hope this information is helpful to you. If you have additional questions about **EXTRANEAL** (icodextrin), please contact your Baxter Renal Representative.



Kuljinder Singh  
Senior Director Medical Affairs, Japan & ANZ  
Baxter Healthcare Pty Limited

Baxter Healthcare Pty Ltd, 1 Baxter Drive, Old Toongabbie, NSW 2146, Australia. Tel: 1800 229 837.  
[www.baxterhealthcare.com.au](http://www.baxterhealthcare.com.au)

Baxter Healthcare Ltd, 33 Vestey Drive, Mt Wellington, Auckland, New Zealand. Tel: 0800 229 837.  
[www.baxter.co.nz](http://www.baxter.co.nz)

BAXTER and EXTRANEAL are trademarks of Baxter International Inc.  
Date of Preparation, 22 March 2023.

# Attention Hospital Pharmacy

## WARNING

### Potential for Incorrect Blood Glucose Reading

22 March 2023

Dear Hospital Pharmacy,

Baxter Healthcare Pty Ltd. would like to notify you of **important safety information** involving patients who use **EXTRANEAL** (icodextrin) peritoneal dialysis solution and who may require the use of blood glucose monitors and test strips.

**Patients receiving EXTRANEAL (icodextrin) peritoneal dialysis solution may have incorrect blood glucose results when using particular blood glucose monitors and test strips.**

**ONLY use glucose monitors and test strips that are glucose-specific. These methods are common in clinical laboratories. Contact the manufacturer of the glucose monitors and test strips to determine the method that is used. Visit [www.glucosafety.com](http://www.glucosafety.com) for additional information, including a glucose monitor compatibility list.**

The term “glucose-specific” applies to monitors or test strips that are not affected by the presence of maltose or certain other sugars. Because **EXTRANEAL** (icodextrin) peritoneal dialysis solution results in elevated blood levels of maltose, only glucose-specific monitors and test strips should be used.

**DO NOT use glucose monitors or test strips that utilize glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods. In addition, some but not all monitors or test strips that utilize a glucose dehydrogenase flavin-adenine dinucleotide (GDH-FAD) method should not be used.** Use of these methods may result in falsely elevated blood glucose readings in patients using **EXTRANEAL** (icodextrin) due to maltose interference. A blood glucose reading with these monitors that appears to be within the normal range in a patient on **EXTRANEAL** (icodextrin) may mask true hypoglycemia (low blood sugar). This would cause a patient or health care professional not to take the appropriate steps to bring the blood sugar into a normal range. A falsely elevated blood glucose reading could cause a patient to get more insulin than needed. Both of these situations can lead to life-threatening events, including loss of consciousness, coma, neurological damage or death.

Additional considerations for patients who use **EXTRANEAL** (icodextrin):

1. Discontinuing **EXTRANEAL** (icodextrin) use will not immediately address the risk for the potential interference with glucose monitors. Falsely elevated glucose levels may result up to two weeks following cessation of **EXTRANEAL** (icodextrin).
2. To determine what type of method is used for monitoring glucose levels, review the labeling for BOTH the glucose monitor and the test strips used. If in doubt, contact the manufacturer of the glucose monitors and test strips to determine the method that is used.

**Baxter**

3. If your hospital uses electronic medical records, the above information describing the potential for interference with blood glucose monitors or test strips needs to be entered in a suitable field readily apparent to all users.

For further information, refer to **EXTRANEAL** (icodextrin) prescribing information or visit [www.glucosesafety.com](http://www.glucosesafety.com)

I hope this information is helpful to you. If you have additional questions about **EXTRANEAL** (icodextrin), please contact your Baxter Renal Representative.



Kuljinder Singh  
Senior Director Medical Affairs, Japan & ANZ  
Baxter Healthcare Pty Limited

Baxter Healthcare Pty Ltd, 1 Baxter Drive, Old Toongabbie, NSW 2146, Australia. Tel: 1800 229 837.  
[www.baxterhealthcare.com.au](http://www.baxterhealthcare.com.au)

Baxter Healthcare Ltd, 33 Vestey Drive, Mt Wellington, Auckland, New Zealand. Tel: 0800 229 837.  
[www.baxter.co.nz](http://www.baxter.co.nz)

BAXTER and EXTRANEAL are trademarks of Baxter International Inc.  
Date of Preparation, 22 March 2023.



# Attention Laboratory Services

## WARNING

### Potential for Incorrect Blood Glucose Reading

22 March 2023

Dear Laboratory Services,

Baxter Healthcare Pty Ltd. would like to notify you of **important safety information** involving patients who use **EXTRANEAL** (icodextrin) peritoneal dialysis solution and who may require the use of blood glucose monitors and test strips.

**Patients receiving EXTRANEAL (icodextrin) peritoneal dialysis solution may have incorrect blood glucose results when using particular blood glucose monitors and test strips.**

**ONLY use glucose monitors and test strips that are glucose-specific. These methods are common in clinical laboratories. Contact the manufacturer of the glucose monitors and test strips to determine the method that is used. Visit [www.glucosafety.com](http://www.glucosafety.com) for additional information, including a glucose monitor compatibility list.**

The term “glucose-specific” applies to monitors or test strips that are not affected by the presence of maltose or certain other sugars. Because **EXTRANEAL** (icodextrin) peritoneal dialysis solution results in elevated blood levels of maltose, only glucose-specific monitors and test strips should be used.

**DO NOT use glucose monitors or test strips that utilize glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods. In addition, some but not all monitors or test strips that utilize a glucose dehydrogenase flavin-adenine dinucleotide (GDH-FAD) method should not be used.** Use of these methods may result in falsely elevated blood glucose readings in patients using **EXTRANEAL** (icodextrin) due to maltose interference. A blood glucose reading with these monitors that appears to be within the normal range in a patient on **EXTRANEAL** (icodextrin) may mask true hypoglycemia (low blood sugar). This would cause a patient or health care professional not to take the appropriate steps to bring the blood sugar into a normal range. A falsely elevated blood glucose reading could cause a patient to get more insulin than needed. Both of these situations can lead to life-threatening events, including loss of consciousness, coma, neurological damage or death.

Additional considerations for patients who use **EXTRANEAL** (icodextrin):

1. Discontinuing **EXTRANEAL** (icodextrin) use will not immediately address the risk for the potential interference with glucose monitors. Falsely elevated glucose levels may result up to two weeks following cessation of **EXTRANEAL** (icodextrin).
2. To determine what type of method is used for monitoring glucose levels, review the labeling for BOTH the glucose monitor and the test strips used. If in doubt, contact the manufacturer of the glucose monitors and test strips to determine the method that is used.

**Baxter**

3. If your hospital uses electronic medical records, the above information describing the potential for interference with blood glucose monitors or test strips needs to be entered in a suitable field readily apparent to all users.

For further information, refer to **EXTRANEAL** (icodextrin) prescribing information or visit [www.glucosesafety.com](http://www.glucosesafety.com)

I hope this information is helpful to you. If you have additional questions about **EXTRANEAL** (icodextrin), please contact your Baxter Renal Representative.



Kuljinder Singh  
Senior Director Medical Affairs, Japan & ANZ  
Baxter Healthcare Pty Limited

Baxter Healthcare Pty Ltd, 1 Baxter Drive, Old Toongabbie, NSW 2146, Australia. Tel: 1800 229 837.  
[www.baxterhealthcare.com.au](http://www.baxterhealthcare.com.au)

Baxter Healthcare Ltd, 33 Vestey Drive, Mt Wellington, Auckland, New Zealand. Tel: 0800 229 837.  
[www.baxter.co.nz](http://www.baxter.co.nz)

BAXTER and EXTRANEAL are trademarks of Baxter International Inc.  
Date of Preparation, 22 March 2023.